Actively Recruiting
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Led by Tanta University · Updated on 2025-11-18
44
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
CONDITIONS
Official Title
Evaluating the Safety and Efficacy of Duloxetine in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age more than 18 years old
- Both males and females can participate
- Patients must have suitable indications for ERCP due to suspected pancreato-biliary disorders
- Blood amylase and lipase levels before ERCP must be within normal limits
You will not qualify if you...
- Uncontrolled diabetes mellitus
- Severe bleeding tendency
- Impaired renal function (serum creatinine > 2 mg/dL or creatinine clearance <30 ml/min)
- Severe heart disease
- Previous biliary or pancreatic sphincterotomy, dilatation, or stenting of either duct
- Currently pregnant or nursing
- Admission due to established pancreatitis before ERCP
- Unwillingness to undergo ERCP
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta Unuversity
Tanta, Egypt, 31527
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here